Alpha Tau Medical Ltd. (DRTS) - Rasio tanggungan utang jangka dawa marang modal

The price history of Alpha Tau Medical Ltd. (DRTS) shares on the GURU.Markets platform reflects a metric that currently stands at 0.29. The business is disrupting the onco-radiology niche through the implementation of the Alpha DaRT system, driving recurring applicator purchases by clinics. Patents on isotope delivery and strict nuclear safety oversight ensure a high barrier to entry. However, financial stability relies on a single product, leaving revenues dependent on the pace of expansion in the US.

To stress-test asset resilience, it is crucial for an investor to evaluate the long-term debt-to-equity ratio, which determines the business's dependence on external borrowed financing. In the context of developing automated radiological control systems, the historical long-term debt-to-equity level provides insight into the ability of Alpha Tau Medical Ltd. (DRTS) to scale high-tech IT platforms without a critical increase in credit leverage.